Laboratory and clinical studies on cefotiam hexetil

Yuuei Irabu, Tomokazu Kakazu, Kazunori Tamaki, Hiroshi Fukuhara, Mutsuko Miyagi, Hiroaki Nakamura, Hiroshi Kaneshima, Katsuyoshi Shimoji, Keizou Kitsukawa, Kenji Mori, Yoshiteru Shigeno, Yuutoku Kinjou, Atsushi Saito, Isamu Nakasone, Shinkou Taira, Nobuchika Kusano, Seitetsu Hokama

Research output: Contribution to journalArticlepeer-review


We performed laboratory and clinical studies on cefotiam hexetil (CTM-HE), a new cephalosporin and pro-drug of cefotiam, with the following results. 1) Antimicrobial activity The minimum inhibitory concentrations (MICs) of cefotiam (CTM) for a total 134 strains, consisting of 12 standard strains and 122 clinical isolates, were determined and compared with those of cefaclor (CCL). The activity of CTM against Klebsiella pneumoniae, Staphylococcus aureus, Haemophilus influenzae and Branhamella catarrhalis was superior to that of CCL. The activity of CTM against Streptococcus pneumoniae was equally potent to that of CCL. MICs of both antibiotics against strains of Pseudomonas aeruginas were more than 100 μg/ml. 2) Clinical efficacy CTM-HE 300 or 600 mg/day was given to 4 patients with pneumonia, 3 with acute bronchitis and 3 with acute exacerbation of chronic bronchitis for 5 to 14 days. Clinical response was excellent in 1, good in 4, fair in 4 and not assessable in 1 patient. Vomiting as a side effect was observed in one patient. Altered laboratory findings were observed in 2 patients with transient elevation of GOT and in one case with an increase in eosinophils.

Original languageEnglish
Pages (from-to)441-452
Number of pages12
Publication statusPublished - 1988
Externally publishedYes


  • Cefotaim hexetil

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology


Dive into the research topics of 'Laboratory and clinical studies on cefotiam hexetil'. Together they form a unique fingerprint.

Cite this